Anti-viral Therapy in Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03282916

Recruitment Status : Active, not recruiting

First Posted : September 14, 2017

Last Update Posted : March 13, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

National Institutes of Health (NIH)

National Institute on Aging (NIA)

Information provided by (Responsible Party):

Davangere P. Devanand, New York State Psychiatric Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	December 2023
Estimated Study Completion Date :	December 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, Mintz A, Wisniewski T, Acosta E, Pollina J, Katsikoumbas M, Bell KL, Pelton GH, Deliyannides D, Prasad KM, Huey ED. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial. BMJ Open. 2020 Feb 6;10(2):e032112. doi: 10.1136/bmjopen-2019-032112.

To Top